NetworkNewsBreaks – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) Has “Buy” Rating Reiterated at Aegis Capital
Aegis Capital reiterated a ‘Buy’ rating and price target of $41 on shares of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) following the company’s recent report that eptinezumab met the primary and key secondary endpoints in PROMISE 1, a phase 3 pivotal clinical trial evaluating patients with frequent episodic migraine. The analyst noted that this positive news pushes the company one step closer to FDA approval for eptinezumab. Additionally, an upcoming catalyst for the company is the PROMISE 2 data expected in the first half of 2018. For more information, visit www.alderbio.com About Alder BioPharmaceuticals Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical…







